Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using Latanoprost 0.01% solution for hair loss and seeking success stories. It mentions that Latanoprost works differently from Minoxidil, Finasteride, and RU58841.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

OP has been using oral minoxidil (5mg) and oral dutasteride (0.5mg) but sees little progress and is unsure if they should continue. Other users suggest being consistent, giving it more time, and addressing scalp inflammation.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

The user experienced significant hair regrowth using topical finasteride/minoxidil and oral minoxidil/dutasteride, with some mild side effects that diminished over time. They plan to add microneedling to their regimen and have seen hair shedding cycles every six months, followed by thicker regrowth.

Latanoprost at 0.1% concentration is used to increase hair counts, often mixed with Minoxidil and Finasteride. Users report noticeable results in about 3 months.

A 23-year-old woman with androgenetic alopecia (AGA) is using minoxidil, rosemary oil, and dermastamping for hair loss, and is concerned about the effectiveness of minoxidil. She follows a detailed hair care routine and takes supplements like inositol, magnesium, saw palmetto, iron, multivitamins, vitamin D, and B12.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

The conversation discusses the use of 0.1% latanoprost for hair regrowth, with concerns about cost and dependency. The user currently uses dutasteride and oral minoxidil and is considering adding latanoprost to their regimen.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

The conversation discusses purchasing Avodart (dutasteride) at a low price, with the OP using 1mg daily for hair loss. Users inquire about the source, and OP confirms buying from Oxford Pharmacy in the UK.

A 22-year-old female with AGA due to PCOS is using 5% minoxidil foam and 2mg finasteride daily, and is seeking advice on microneedling frequency and safety. Concerns about finasteride dosage and its effects on PCOS were discussed, with emphasis on trusting the prescribed treatment plan.

The user experienced initial improvement in hair loss with oral finasteride and minoxidil but later faced increased shedding and thinning. They switched to dutasteride, hoping for better results, while continuing topical minoxidil.

User discusses Latanoprost as potential hair loss treatment and considers combining it with oral minoxidil for better results. Seeking opinions on effectiveness and expense.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The conversation discusses Procapil, a treatment for hair loss containing Apigenin and Oleanolic acid. Users are sharing their experiences and asking if anyone has tried it.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

A user with alopecia areata is considering treatment options like injections or Olumiant but is concerned about cost and whether delaying treatment will lead to permanent hair loss. They are seeking alternative treatments that are more affordable for a college student.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Switching from liquid to foam Minoxidil to avoid scalp irritation, with a method to melt the foam for easier application. Users discuss alternatives and personal experiences with Minoxidil, including issues with propylene glycol and different application methods.

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.

Ramsko1's experience with a hair loss regimen of oral minoxidil, dutasteride, ketoconazole cream, and dermarolling, which they started after considering taking their own life due to hair loss. Other users replied to offer support and ask questions about specific treatments.

The conversation discusses using Bimatoprost for eyebrow regrowth and its potential use on the hairline, with concerns about cost and side effects. Alternatives like topical Minoxidil are mentioned, but the user is worried about aging and acne.

Naepo's 5-month progress report detailing their journey of treating male pattern baldness with dutasteride and oral minoxidil, which has already resulted in an encouraging improvement in hair density. Others have responded with appreciation for the thorough report and asked further questions about Naepo's educational background.

The user discusses using Minoxidil for 2 months and Aminexil for 3 months for hair regrowth. They are hopeful about the results.

The user is discouraged after nearly a year of using oral minoxidil and dutasteride without seeing desired hair regrowth. Suggestions include increasing dutasteride dosage, trying hair transplants, and considering other treatments like derma stamping or topical solutions.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.